VCEL vs. RXRX, APGE, KYMR, ADMA, ACLX, BEAM, TWST, IMCR, SANA, and DNLI
Should you be buying Vericel stock or one of its competitors? The main competitors of Vericel include Recursion Pharmaceuticals (RXRX), Apogee Therapeutics (APGE), Kymera Therapeutics (KYMR), ADMA Biologics (ADMA), Arcellx (ACLX), Beam Therapeutics (BEAM), Twist Bioscience (TWST), Immunocore (IMCR), Sana Biotechnology (SANA), and Denali Therapeutics (DNLI). These companies are all part of the "biological products, except diagnostic" industry.
Recursion Pharmaceuticals (NASDAQ:RXRX) and Vericel (NASDAQ:VCEL) are both mid-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their community ranking, dividends, analyst recommendations, institutional ownership, risk, media sentiment, profitability, earnings and valuation.
Vericel has a net margin of 0.22% compared to Vericel's net margin of -765.90%. Recursion Pharmaceuticals' return on equity of 0.21% beat Vericel's return on equity.
Recursion Pharmaceuticals has a beta of 0.85, meaning that its stock price is 15% less volatile than the S&P 500. Comparatively, Vericel has a beta of 1.74, meaning that its stock price is 74% more volatile than the S&P 500.
In the previous week, Vericel had 1 more articles in the media than Recursion Pharmaceuticals. MarketBeat recorded 11 mentions for Vericel and 10 mentions for Recursion Pharmaceuticals. Recursion Pharmaceuticals' average media sentiment score of 0.48 beat Vericel's score of 0.45 indicating that Vericel is being referred to more favorably in the news media.
Vericel has higher revenue and earnings than Recursion Pharmaceuticals. Vericel is trading at a lower price-to-earnings ratio than Recursion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Recursion Pharmaceuticals currently has a consensus price target of $12.75, indicating a potential upside of 35.35%. Vericel has a consensus price target of $46.80, indicating a potential downside of 3.21%. Given Vericel's higher possible upside, equities analysts clearly believe Recursion Pharmaceuticals is more favorable than Vericel.
Vericel received 315 more outperform votes than Recursion Pharmaceuticals when rated by MarketBeat users. Likewise, 62.22% of users gave Vericel an outperform vote while only 51.22% of users gave Recursion Pharmaceuticals an outperform vote.
89.1% of Recursion Pharmaceuticals shares are owned by institutional investors. 15.8% of Recursion Pharmaceuticals shares are owned by company insiders. Comparatively, 5.2% of Vericel shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Summary
Vericel beats Recursion Pharmaceuticals on 13 of the 18 factors compared between the two stocks.
Get Vericel News Delivered to You Automatically
Sign up to receive the latest news and ratings for VCEL and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding VCEL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
